Oracle, Parexel International Corporation and Bioclinica. are Dominating the Asia-Pacific Randomization and Trial Supply Management (RTSM) Market in 2021

Asia-Pacific Randomization and Trial Supply Management (RTSM) Market is expected to grow with the CAGR of 14.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

Asia-Pacific randomization and trial supply management (RTSM) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.  

The major players dealing in Asia-Pacific randomization and trial supply management (RTSM) market are introducing strong range of products provider along with receiving large number of CE mark approvals for launching new products into the market.

For instance,

  • In June 2020, Oracle unveiled their Clinical One Data Collection Cloud Service which would help in refined data collection during clinical trials. This new launch by the organization has enhanced the company’s overall revenue for market.

Oracle is the dominating player in randomization and trial supply management (RTSM) market. The other key players existing in the market includes are Cenduit LLC, ICON plc, Parexel International Corporation, IBM Corporation, 4G Clinical, Ennov, Bioclinica., eClinical Solutions LLC., Statistics & Data Corporation, Baiao known,  Zhejiang Taimei Medical Technology Co., Ltd., Medrio, Inc., IDDI., and Medidata Solutions, Inc.(Dassault Systemes) among others.

Asia-Pacific Randomization and Trial Supply Management (RTSM) Market Oracle

Oracle was found in 1977 and is headquartered in Texas, United States. The company is engaged in helping people see data in new ways, discover insights and unlock endless possibilities. The company has multiple business segments as cloud and license, hardware and services where cloud and license are the market focused segment. The company has Infrastructures and life science applications where life science applications is the market focused category. 

For instance:

  • In May 2020, PeachTree Bioresearch Solutions agrees to use Oracle’s Cloud service systems to streamline the clinical trial data management. This thereby improved company profile and gained more customers.

The company also has global presence in Asia Pacific, Europe, and Middle East and Africa, The Americas. The company has subsidiaries like Taleo, Aconex, Textura Corporation, and Agile among others.

Parexel International Corporation

Parexel International Corporation is headquartered in Massachusetts in United States which was founded in 1982. Company is leading in providing of wide range of drug development abilities to the worldwide CROs. The company offers a range of leading software and service categories such as Parexel biotech, clinical development, consulting, outsourcing services, medical aaffairs, real-world evidence and late phase where clinical development is the market focused category.

For instance:

  • In May 2020, Parexel International Corporation (U.S.) joined with ACRO to help the administrator and overseas COVID-19 testing in the U.K. It will help the company to maintain their stable position in market for being top solutions provider for better delivery of new therapies
  • In January 2020, Parexel International Corporation (U.S.) announced the TIGeR-PaC’s Trans-Arterial Micro-Perfusion (TAMPTM) has reached its first patient enrollment as successfully proceeding to phase III clinical trials. Overall trial enrolment is on schedule and is exceeding 20 percent worldwide. It helped the company in achieving an extra milestone in the fields of clinical trials.

The company has presence in Asia Pacific, Europe, and Middle East and Africa, The Americas. The subsidiaries are Perceptive Informatics Inc. (U.K.), PAREXEL International (India) Private Limited (India), PAREXEL MMS Europe Limited (U.K.), PAREXEL International (Thailand) Co Ltd (Thailand), and DATALABS INC (U.S.) among others.


Bioclinica is headquartered in New Jersey, U.S. The company is engaged in providing medical science and technology expertise to life science industry, advancing the development of medical therapies for people around world. Company also has wide product portfolio in medical imaging, clinical trial software, specialty solutions, drug safety where clinical trial software is market focused category.

For instance:

  • In January 2021, Bioclinica announced that they made successful partnership with IKCON PHARMA (a subsidiary/affiliate of IKCON TECHNOLOGIES INC), a Clinical Research Organization (CRO) & technology services company. This partnership helped both companies in improving their clinical trial management services
  • In April 2019, Bioclinica announced that they launched non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH), to help sponsors develop therapeutics using medical imaging and other biomarkers in clinical trials. This has enhanced company’s solution portfolio and revenue for the future market

The company has presence in North America, Europe, and Asia-Pacific.